Is it too much of a good thing? A new era in phosphate binder therapy in ESRD

Journal of the American Society of Nephrology

Volumn 26, Issue 10, 2015, Pages 2311-2313

  Qunibi, Wajeh Y ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACETATE; FERRIC CITRATE; IRON; LANTHANUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; SEVELAMER CARBONATE; ANTIANEMIC AGENT; FERRIC ION;

ANEMIA; DIET SUPPLEMENTATION; EDITORIAL; END STAGE RENAL DISEASE; HUMAN; HYPERPHOSPHATEMIA; IRON ABSORPTION; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; FEMALE; MALE;

ANEMIA; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HUMANS; IRON; MALE;

EID: 84942867599     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015020135     Document Type: Editorial

References (20)

1. Locatelli F, Del Vecchio L, Violo L, Pontoriero G: Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: A comparison of safety profiles. Expert Opin Drug Saf 13: 551-561, 2014.
2. KDOQI; National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 47[Suppl 3]: S11-S145, 2006.
3. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with lowhematocrit values in patientswith cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998.
4. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006.
5. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006.
6. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009.
7. Epogen: Epogen Package Insert, US Food and Drug Administration, Thousand Oaks, CA, Amgen, 2011.
8. Centers for Medicare & Medicaid Services (CMS), HHS: Medicare program; end-stage renal disease prospective payment system. Final rule. Fed Regist 75: 49029-49214, 2010.
9. Weiner DE, Winkelmayer WC: Commentary on 'The DOPPS practice monitor for U.S. dialysis care: Update on trends in anemia management 2 years into the bundle': Iron(y) abounds 2 years later. Am J Kidney Dis 62: 1217-1220, 2013.
10. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2: 279-335, 2012.
11. Arbor Research Collaborative for Health:DOPPS Practice Monitor, Ann Arbor, MI, Arbor Research Collaborative for Health, 2014.
12. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, InabaM, Robinson BM: Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses andmortality. Kidney Int 87: 162- 168, 2015.
13. Rostoker G, GriuncelliM, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y: Hemodialysis-associated hemosiderosis in the era of erythropoiesisstimulating agents: A MRI study. Am J Med 125: 991-999.e1, 2012.
14. Vaziri ND: Understanding iron: Promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 61: 992-1000, 2013.
15. Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S; Dialysis Advisory Group of the American Society of Nephrology: Considerations and challenges in defining optimal iron utilization in hemodialysis [published online ahead of print December 26, 2014]. J Am Soc Nephrol doi:ASN.2014090922.
16. Lewis JB, SikaM, KouryMJ, Chuang P, Schulman G, SmithMT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP; Collaborative Study Group: Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol 26: 493-503, 2015.
17. Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Blumenthal SS, Sika M, Niecestro R, Koury MJ, Ma K-N, Greene T, Lewis JB, Dwyer JP; Collaborative StudyGroup: Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol 26: 2578-2587, 2015.
18. Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM: A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5 [published online ahead of print November 4, 2014]. Am J Kidney Dis doi:10.1053/j.ajkd.2014.10.014.
19. Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM; PA21 Study Group: A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 86: 638-647, 2014.
20. Mutell R, Rubin JL, Bond TC, Mayne T: Reduced use of erythropoiesisstimulating agents and intravenous iron with ferric citrate: A managed care cost-offset model. Int J Nephrol Renovasc Dis 6: 79-87, 2013.